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Virus fusionParkinson's disease-associated α-synuclein is an amyloidogenic protein not only expressed in the cytoplasm
of neurons, but also secreted in the extracellular space and internalized into glial cells through a lipid raft-
dependent process. We previously showed that α-synuclein interacts with raft glycosphingolipids through a
structural motif common to various viral and amyloidogenic proteins. Here we report that α-synuclein also
interacts with cholesterol, as assessed by surface pressure measurements of cholesterol-containing
monolayers. Using a panel of recombinant fragments and synthetic peptides, we identiﬁed two distinct
cholesterol-binding domains inα-synuclein. One of these domains, which corresponds to the tilted peptide of
α-synuclein (67–78), bound cholesterol with high afﬁnity and was toxic for cultured astrocytes. Molecular
modeling suggested that cholesterol binds to this peptide with a tilt angle of 46°. α-synuclein also contains a
cholesterol recognition consensus motif, which had a lower afﬁnity for cholesterol and was devoid of toxicity.
This motif is encased in the glycosphingolipid-binding domain (34–45) of α-synuclein. In raft-like model
membranes containing both cholesterol and glycosphingolipids, the head groups of glycosphingolipids
prevented the accessibility of cholesterol to exogenous ligands. Nevertheless, cholesterol appeared to ‘signal’
its presence by tuning glycosphingolipid conformation, thereby facilitating α-synuclein binding to raft-
like membranes. We propose that the association of α-synuclein with lipid rafts involves both the binding of
α-synuclein (34–45) to glycosphingolipids, and the interaction of the fusogenic tilted peptide (67–78) with
cholesterol. Coincidentally, a similar mechanism is used by viruses (HIV-1, HTLV-I, Ebola) which display a
tilted peptide and fuse with host cell membranes through a sphingolipid/cholesterol-dependent process.AC, cholesterol recognition/
phingolipid-binding motif; GSL,
-(3-carboxymethoxyphenyl)-
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α-synuclein is 140 kDa protein expressed in the brain, involved in
the trafﬁc of synaptic vesicles, and associated with Parkinson's disease
(PD) [1]. It belongs to the category of intrinsically disordered proteins
(IDPs) that lack a stable 3D structure in water but can adopt various
conformations depending on environmental factors [2]. Although
generally considered as a cytoplasmic protein, recent data have
shown that α-synuclein is also secreted from neuronal cells [3]. In line
with these data, α-synuclein has been detected in extracellular
biological ﬂuids, including human cerebrospinal ﬂuid and blood
plasma, in both PD and normal human subjects [4]. Several studieshave shown that α-synuclein can penetrate into various cell types,
including neurons, microglia, platelets, and ﬁbroblasts [5–8]. In
addition, α-synuclein oligomers can form annular structures with
pore-like properties that might affect membrane permeability in the
brain cells of PD patients [9].
Several studies have shown that α-synuclein has an afﬁnity for
lipid rafts, suggesting a role for these membrane microdomains
enriched in sphingolipids and cholesterol in the normal and/or the
pathological functions of α-synuclein [6,10–12]. In vitro, α-synuclein
binds to model membranes, especially those containing typical raft
components such as phosphatidylserine [11] and glycosphingolipids
(GSLs) [13]. We recently reported that α-synuclein interacts with
GSLs through a speciﬁc domain spanning amino acid residues 34–45
of the protein [14]. This GSL-binding motif (GBM), which is
structurally conserved among several virus, bacterial, and amyloido-
genic proteins [15], mediates the insertion of α-synuclein in raft-like
membranes containing various GSLs such as gangliosides GM1 and
GM3. A growing body of evidence suggests that these gangliosides
have a strong impact on the biological activity of α-synuclein. On one
hand, GM1 has been shown to inhibitα-synuclein ﬁbrillation [13] and
to promote its internalization into microglial cells [6]. On the other
hand, GM3 markedly affected the function of α-synuclein channels in
membrane bilayers [16]. Interestingly, the GSL that displays the
highest afﬁnity for α-synuclein [14], i.e. GM3, is the most abundant
Fig. 1. Interaction of recombinant α-synuclein with cholesterol. a. Kinetics studies of
recombinant α-synuclein (100 nM) interaction with pure cholesterol (□) or mixed
cholesterol:POPC (1:1, mol:mol) (▲) monolayers. The data show the real-time changes
of surface pressure following injection of 100 nM recombinant α-synuclein beneath
each lipid monolayer prepared at an initial surface pressure of 17 mN.m−1. Each curve
is representative of three separate experiments (SDb10%). b. Interaction of recombi-
nant α-synuclein (100 nM) with pure cholesterol monolayers prepared at various
values of the initial surface pressure. The maximal surface pressure (Δπmax) was
determined after reaching the equilibrium. The critical pressure of insertion (πc) is the
value of the pressure extrapolated at the intercept of the Δπmax=f(πi) slopes.
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view that the interaction of extracellular α-synuclein with glial cells
might play an important role in PD [18].
Apart from GSLs, the exofacial leaﬂet of lipid raft domains contains
two other major lipids, sphingomyelin and cholesterol [19]. Recent data
suggested that α-synuclein has no particular afﬁnity for sphingomyelin
[14]. In contrast, cholesterol has been reported to promote α-synuclein
aggregation in transfectedneuronal cells [20].Moreover, statin treatment
of α-synuclein transgenic mice was associated with a marked reduction
ofα-synuclein aggregation and abrogation of neuronal pathology [21]. A
possible interpretation of these data could be thatα-synuclein physically
interacts with cholesterol and that this lipid controls α-synuclein
aggregation. Yet little is known about the cholesterol-binding properties
of α-synuclein at the molecular level [22].
In thepresent study,wehaveanalyzed the interactionofα-synuclein
with cholesterolwith a combination of physicochemical, computational,
and cellular approaches. The Langmuir ﬁlm balance technique [23] was
used to study the insertion of recombinant α-synuclein (full-length
and fragments) and synthetic α-synuclein peptides into cholesterol-
containing monolayers at the air–water interface. We showed that
although α-synuclein displays a cholesterol recognition/interaction
amino acid consensus sequence (CRAC) spanning amino acid residues
37–43, this domain behaves as a low afﬁnity cholesterol-binding site.
This CRAC domain is encased in the GBM (34–45) of α-synuclein. In
addition,wehave discovered a second, high-afﬁnity cholesterol-binding
motif in the 67–78 region. This domain corresponds to the previously
characterized fusogenic tilted peptide ofα-synuclein [24].We discussed
the respective roles of the GSL and cholesterol-binding domains of
α-synuclein and proposed that GSLs and cholesterol could act in
synergy to promote the insertion of α-synuclein in lipid rafts through a
virus-like fusion mechanism.
2. Materials and methods
2.1. Materials
Recombinant human α-synuclein was obtained from rPeptide
(Bogart, GA). Recombinant α-synuclein fragments [8] were purchased
from ATGen Co., Ltd. (Seongnam-si, South Korea). Synthetic peptides
with a purityN95% were obtained from Schafer-N (Copenhagen,
Denmark). Ultrapure apyrogenic water was from Biorad (Marnes La
Coquette, France). All lipids were purchased from Matreya (Pleasant
Gap, PA).
2.2. Detection of a CRAC domain in α-synuclein
We used the consensus of the cholesterol recognition amino acid
(CRAC) consensus sequence determinedby Jamin et al. [25] (L/V)–X1–5–
(Y)–X1–5–(K,R) to identify potential cholesterol binding domains in
α-synuclein.
2.3. In silico studies of α-synuclein-cholesterol interactions
Molecular modeling studies were performed with the Hyperchem
8 program (ChemCAD, Obernay, France). To generate peptide–
cholesterol complexes, one cholesterol molecule was positioned in
the vicinity of the peptide (manual search for geometric ﬁt). Several
initial conditionswere tested (with distinct orientations of cholesterol
with respect to the tilted peptide) to select the complex having
the highest energy of interaction. In particular, initial conditions in
which themethyl groups of cholesterol were not directed towards the
α-helical peptide did not allow the formation of a stable complex.
Geometry optimization of the selected complex was ﬁrst achieved
using the unconstrained optimization rendered by the Polak–Ribière
conjugate gradient algorithm [14]. Molecular dynamics simulations
were then performed for 10 ns in vacuo with the Bio+ (CHARMM)force ﬁeld [26] of the Hyperchem software suite. The energy of
interaction was determined with the Molegro Molecular Viewer [27].2.4. Lipid monolayer assay
α-Synuclein-lipid interactions were studied with the Langmuir ﬁlm
balance technique [23]. The surface pressure of lipid monolayers [14]
wasmeasured with a fully automatedmicrotensiometer (μTROUGH SX,
Kibron Inc. Helsinki, Finland). All experiments were carried out in a
controlledatmosphere at 20±1 °C. The lipidswere dissolved inhexane:
chloroform:ethanol (11:5:4, vol:vol:vol) at a concentration of
1 mg.mL−1 and stored at−20 °C under saturated nitrogen atmosphere.
Monomolecular ﬁlms of the indicated lipid were spread on ultrapure
water subphases totally devoid of any surfactant contaminant as
described previously [28]. After spreading of the ﬁlm, 5 min was
allowed for solvent evaporation. Stock solutions of recombinant
proteins and synthetic peptides were prepared in ultrapure water,
stored at−20 °Cand thawed immediately before use. 8 μL of theprotein
(or the synthetic peptide) solution were injected in the subphase
(800 μL, pH 7) with a 10-μl Hamilton syringe, and pressure increases
producedwere continuously recorded as a function of time. The surface
pressure at the time of injection is indicated in the ﬁgure legends.
Control experiments were run in parallel to ensure that the injection of
8 μL of the ultrapure water in which proteins and peptides were
dissolved did not induce by itself any surface pressure change. The
datawere analyzedwith the FilmWareX3.57program(Kibron Inc.). The
accuracy of the system under our experimental conditions
was±0.25 mN.m−1 for surface pressure.
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Primary cultures of rat cortical astrocytes were seeded in 96-well
culture plates and treated for 24 h with the indicated concentrations
of peptides. Cellular toxicity was assessed by theMTS assay (Promega,
Charbonnieres, France) as described by Crowet et al. [24].
3. Results
3.1. α-Synuclein interacts with cholesterol monolayers
First, we studied the interaction of full-length recombinant
α-synuclein with cholesterol monolayers at the air–water interface. In
these experiments, cholesterol was spread on the surface of a water
meniscus and after equilibration of the monolayer, α-synuclein was
injected in the subphase at a ﬁnal concentration of 100 nM. The
interaction of α-synuclein with cholesterol was quantiﬁed by measur-
ing in real-time the changes of the surface pressure of the monolayer
(Δπ). As shown in Fig. 1a,α-synuclein induced a rapid surface pressure
increase of the cholesterol monolayer, with an initial velocity (vi) of
0.6 mN.m−1.min−1. When α-synuclein was injected underneath a
mixed cholesterol-phosphatidylcholine (1:1, mol:mol) monolayer, the
interactionproceededat a similar (vi) and the (Δπ)was about 50%of the
value obtained with pure cholesterol monolayers. This indicates that in
mixed monolayers, α-synuclein interacts almost exclusively with
cholesterol, which represents 50% of the lipids, and not with
phosphatidylcholine. In order to measure the avidity of the protein for
cholesterol, experiments were performed with cholesterol monolayers
prepared at various values of the surface pressure (initial surface
pressure, πi). The data are expressed as Δπmax=f(πi) curves. As shown
in Fig. 1b, the values ofΔπmax gradually decreased asπi increased,which
demonstrates the speciﬁcity of the interaction. These experiments alsoFig. 2. Interaction ofα-synuclein fragments with cholesterol and GM3monolayers. a. Kinetic
prepared at an initial surface pressure of 17 mN.m−1. b. Kinetics studies of α-synuclein[1–60
surface pressure of 15 mN.m−1. Each curve is representative of three separate experiments (S
interaction with cholesterol monolayers prepared at an initial surface pressure of 15 mN.m−1
α-synuclein peptides 34–45 (□) and 67–78 (■) with cholesterol monolayers prepared at vallowed to determine the critical pressureof insertion (πc) of theprotein
for the monolayer as the extrapolated value of πi at Δπmax=0. It
represents the surface pressure of the monolayer above which no
further interaction occurs, because the lipids are too densely packed. In
this case, πc was estimated to 37.5 mN.m−1, which is above the
threshold value of 30 mN.m−1 measured in vivo for a real plasma
membrane [29]. Overall these data indicate that α-synuclein is a
cholesterol-binding protein.
3.2. GM3 and cholesterol binding sites map to distinct domains of
α-synuclein
Several experiments were then performed in order to map the
cholesterol-binding domain of α-synuclein. First, we analyzed the
lipid-binding properties of two α-synuclein fragments (1–60 and 61–
140) encompassing the whole protein sequence. These fragments
were injected underneath cholesterol or GM3 monolayers. As
expected, fragment 1–60 which contains the GBM of α-synuclein
(domain 34–45) strongly interacted with GM3 monolayers, whereas
fragment 61–140 did not (Fig. 2a). However, both fragments could
efﬁciently interact with cholesterol, indicating that α-synuclein
contains two distinct cholesterol-binding domains (Fig. 2b). The
presence of a CRAC domain (37-VLYVGSK-43) in the GBM could
explain the cholesterol-binding properties of the 1–60 fragment. To
test this possibility, we analyzed the interaction of a synthetic GBM
peptide (fragment 34–45) with cholesterol. The data of Fig. 2c showed
that this short peptide interacted with cholesterol monolayers,
indicating that the CRAC domain of α-synuclein is functional. Yet
there is no CRACmotif in the 61–140 fragment which could explain its
association with cholesterol. However there is a tilted peptide (67-
GGAVVTGVTAVA-78) which has been previously shown to penetrate
in themembrane and induce toxicity for neuroblastoma cells [24]. Thes studies ofα-synuclein[1–60] (□) andα-synuclein[61–140] (▲) with GM3monolayers
] (□) and α-synuclein[61–140] (▲) with cholesterol monolayers prepared at an initial
Db10%). c. Kinetics studies of syntheticα-synuclein peptides 34–45 (□) and 67–78 (■)
. Each curve is representative of three separate experiments (SDb10%). d. Interaction of
arious values of the initial surface pressure.
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capability to bind cholesterol. As a matter of fact, the 67–78 peptide
efﬁciently interacted with cholesterol (Fig. 2c). To compare the
respective afﬁnity of peptides 34–45 and 67–78 for cholesterol, we
measured the interaction of both peptides with cholesterol mono-
layers prepared at various values of πi. (Fig. 2d). The data showed that
the tilted peptide 67–78 has a higher afﬁnity for cholesterol than the
GBMpeptide 34–45 (πc of 50 and 36 mN.m−1, respectively for the 67–
78 and 34–45 peptides).3.3. Molecular dynamics simulations ofα-synuclein-cholesterol interactions
When tilted peptides insert into the membrane, they adopt a
typical topology with an angle of ca. 45° towards the membrane plane
[30]. Thus it was critical to assess whether such a tilted orientation is
compatible with an interaction with cholesterol. Molecular dynamics
simulations were performed to unravel the structural basis of the high
afﬁnity interaction between the tilted domain of α-synuclein and
cholesterol. In both the membrane- and micelle-bound structures of
α-synuclein, the tilted peptide belongs to an α-helix [31,32]. Thus, an
helical fragment containing the tilted domain was retrieved from the
micellar structure and merged with cholesterol (Fig. 3). Docking
studies revealed that the 69–79 fragment of α-synuclein displays a
potential binding site for cholesterol. Themolecular complex between
α-synuclein and cholesterol was chieﬂy stabilized by van der Waals
interactions involving amino acid residues 69–76, with a calculated
energy of interaction of −36 kJ.mol−1(Fig. 3a). An additional
hydrogen bond between the amide group of Asn-79 and the OHFig. 3.Molecular dynamics simulations of the interaction between cholesterol and theα-synucl
from the pdb entry 1QX8 of micelle-bound α-synuclein [31]. This domain contains the comple
molecular dynamics simulations of the cholesterol/α-synuclein complex were performedwith
betweencholesterol and a fragment ofα-synuclein spanning residues68–79. A detailed analysis
upper left panel (a). A tube rendering of the model is shown in (b). The α-helix of α-synucle
cholesterol interacts with A-69, V-70, T-72, G-73, and A-76 through van derWaals interactions
adapts its 3D structure to curl in this crevice. The OH group of cholesterol forms a H-bond with
surface complementarity between the tiltedpeptide ofα-synucleinand cholesterol is illustrated
ofα-synuclein and themain axis of cholesterol is 46° (d). Top views of the complex in tube (e) a
the tilted fragment.group of cholesterol could also stabilize the complex, so that the total
energy of interaction reached −52 kJ.mol−1. Most importantly, the
peptide bound to cholesterol fully retained its tilted orientation
(Fig. 3b–d). An angle of 46° was measured between the main axis of
cholesterol and the peptide (Fig. 3d). The tilt angle is also well visible
when the complex is observed from the extracellular side of the
membrane (Fig. 3e). The surface views of the complex show how
cholesterol has adapted its shape during the simulations to ﬁll the
cavities of the peptide surface (Fig. 3c and f). To assess the robustness
of our model, subsequent molecular dynamics simulations were
performed for 10 ns (Fig. 4). Snapshots were taken every nanosecond
during 10 ns of simulations to follow the trajectory of cholesterol
bound to α-synuclein (Fig. 4a). It can be seen that the geometry of the
complex was remarkably stable, cholesterol remaining tightly bound
to the tilted peptide. Minor ﬂuctuations of cholesterol position in its
binding site were noted essentially in the polar head (OH group) and
apolar tail (isooctyl chain) of cholesterol. A plot of the calculated
energy of interaction as a function of the simulation time is shown in
Fig. 4b. After 10 ns of molecular dynamics simulations of the peptide–
cholesterol complex, the energy of interaction was 94% of its initial
value. These in silico data were consistent with the physicochemical
analysis of cholesterol binding to the tilted peptide of α-synuclein.3.4. Ganglioside GM3 and cholesterol act in synergy to facilitate the
insertion of α-synuclein in raft-like membranes
The presence of binding sites for GSLs and cholesterol is consistent
with the high afﬁnity of α-synuclein for lipid rafts [6]. In this respect, iteindomain containing the tilted peptide. The 63–79 fragment ofα-synucleinwas retrieved
te tilted peptide of α-synuclein (amino acid residues 67–78). Geometry optimization and
the Hyperchem program as described inMaterials andmethods. The best ﬁt was obtained
of the energyof interaction of the cholesterol/α-synuclein 68–79 complex is shownon the
in (α-syn) is colored in red, and cholesterol (tubes+dots) in yellow. The apolar part of
. These apolar residues form a winding valley on the surface of theα-helix and cholesterol
the oxygen atom of the amide group belonging to the side chain of N-79 (dotted line). The
bya surface viewof the complex (c). The angle between thehelix axis of the tilted fragment
nd surface rendering (f) showed that the cholesterolmoleculewraps around theα-helix of
Fig. 4. Evolution of cholesterol-α-synuclein interactions over 10 ns of molecular
dynamics simulations. Molecular dynamics simulations of the cholesterol-α-synuclein
complex were further conducted for 10 ns from the starting conditions of Fig. 3.
Iterative snapshots taken every nanosecond showing the movements of cholesterol
over the 10 ns period. The ten cholesterol molecules (in blue) are superimposed on the
structure of the tilted peptide with a white surface rendering. To improve clarity, only
one structure of the tilted peptide is shown. b. Evolution of the energy of interaction
calculated at various times during the molecular dynamics simulations. The results are
expressed as the percentage of the energy of interaction detailed in Fig. 3 (starting
conditions).
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like monolayers containing both ganglioside and cholesterol molecules.
The accessibility of cholesterol to exogenous ligands in these mixed
monolayers was assessed by injecting β-methyl-cyclodextrin (βMCD)
underneath the monolayer [33]. As shown in Fig. 5a, βMCDwas able to
extract cholesterol from a pure cholesterol monolayer, inducing a
dramatic decrease in the surface pressure after each βMCD injection. A
similar effectwasobservedwhenβMCDwas addedunderneath amixed
cholesterol-phosphatidylcholine (1:1, mol:mol) monolayer (Fig. 5b).
However, when cholesterol was mixed with phosphatidylserine, the
amplitude of the surface pressure decrease was weak, indicating that
this phospholipid partially limits the accessibility of βMCD to
cholesterol. Finally, βMCD could not extract cholesterol from mixed
GM3-cholesterol (1:1, mol:mol) monolayers, showing that the gangli-
oside totally masked cholesterol to exogenous ligands.
Then we analyzed the interaction of α-synuclein with mixed GM3-
cholesterolmonolayers (Fig. 5c–d). Thepresenceof cholesterol in aGM3
monolayer considerably accelerated the insertion of α-synuclein: vi of
1.0 and 3.4 mN.m−1.min−1 respectively for pure GM3 andmixed GM3-
cholesterol monolayers (Fig. 5c). However, the effect was not due to
an increase in afﬁnity since the πc value determined for mixed GM3-
cholesterol monolayers, i.e. 36.3 mN.m−1 (Fig. 5d) was similar to
37.5 mN.m−1 for pure cholesterol (Fig. 1b) and slightly inferior to
41.3 mN.m−1 for pure GM3 monolayers [14]. Since α-synuclein does
not initially detect the presence of cholesterol because it is masked by
GM3, it can be reasonably assumed that cholesterol optimizes theconformationof GM3 so that it can be recognized by the proteinwithout
any lag. Indeed, we have recently demonstrated that cholesterol could
tune GSL conformation, resulting in the facilitation of Alzheimer's β
peptide insertion in raft-like membranes [28].
3.5. α-Synuclein neuroxicity involves the tilted fragment, but not the
GBM/CRAC domain
Previous data have shown that the tilted peptide of α-synuclein
permeabilizes liposomes and is toxic for neuroblastoma cells [24].
Because gangliosideGM3 is preferentially expressed in astrocytes rather
than in neurons [17], we investigated the potential toxicity of the tilted
peptide for primary astrocytes. In this experiment we used the MTS
assaywhichmeasures the reduction ofmitochondrial activity. The same
assay has been used by Crowet et al. [24] to evaluate the toxicity of the
tilted peptide in neuroblastoma cells. As shown in Fig. 6, a 24-hour
treatment of astrocytes with the α-synuclein 67–78 peptide induced a
dose-dependent decrease in the number of active cells. Therefore, our
data conﬁrmed and extended those obtained by Crowet et al. [24] with
neuroblastoma cells. In contrast, the treatment with the α-synuclein
34–45 peptide did not induce any toxicity at concentrations up to
400 μM. Thus, although both the 34–45 and 67–78 peptides are able to
interact with cholesterol, only the 67–78 peptide appeared to be toxic
for astrocytes.
4. Discussion
4.1. Functional characterization of cholesterol-binding domains
In this study we have established that α-synuclein contains one
GSL and two cholesterol binding domains. Previous data from our
group indicated that the GSL-binding domain lies between amino acid
residues 34 and 45 [14]. This is conﬁrmed by the strong interaction of
the 1–60 fragment of α-synuclein with ganglioside monolayers,
together with the lack of interaction of the 61–140 fragment (Fig. 2).
Interestingly, both fragments were found to bind to cholesterol
monolayers, revealing the presence of two distinct cholesterol
binding domains in the structure of α-synuclein. These domains
were delineated as α-synuclein 37–43 (CRAC motif) and α-synuclein
67–78 (tilted peptide). The Langmuir ﬁlm technique was used to
evaluate the relative afﬁnity of both domains for cholesterol. In these
experiments, a constant amount of protein was added underneath
several cholesterol monolayers prepared at various values of the
surface pressure (initial surface pressure, πi). Indeed, the value of
Δπmax generally decreases as πi increases, because the insertion of the
protein within the cholesterol monolayer is expected to be easier at
low surface pressures, where the lipid molecules are not densely
packed. The extrapolated value of πi at Δπmax=0, referred to as the
critical pressure of insertion (πc) represents the surface pressure of
the monolayer above which no further interaction occurs, because the
lipids are so densely packed that the protein has not enough afﬁnity
for the lipids to substitute lipid–lipid for protein–lipid interactions.
The higher the value of πc is, the higher is the afﬁnity of the protein
for cholesterol. Accordingly, the tilted peptide of α-synuclein (πc of
50 mN.m−1) has a higher afﬁnity for cholesterol than the CRAC
domain (πc of 36 mN.m−1). Moreover, these data indicate that the
tilted peptide might have access to the apolar parts of cholesterol
that are buried in the membrane. In contrast, the CRAC domain of
α-synucleinmighthaveanaccess limited to theOHgroupof cholesterol
in the polar–apolar interface of themembrane. Thus, the physicochem-
ical properties of the CRAC domain are consistent with a superﬁcial
interaction ofα-synucleinwith cholesterolmonolayers, as illustrated in
Fig. 7a. This is the type of interaction that probably occurs in our
monolayer assay, since the πc recorded for full-length α-synuclein
(37.5 mN.m−1) is close to the πc of the CRAC domain alone
(36 mN.m−1). The situation is totally different when α-synuclein is
Fig. 5. Interaction of α-synuclein with mixed cholesterol/GM3 monolayers. a–b. Accessibility of cholesterol to βMCD. A monolayer of pure cholesterol (a) was prepared at an initial
surface pressure of 32 mN.m−1. After stabilization of the cholesterol monolayer, βMCD (10 μM)was injected in the subphase, inducing a dramatic surface pressure decrease (Δπ1). A
second injection of βMCD (ﬁnal concentration of 20 μM) further decreased the surface pressure (Δπ2). This experiment was repeated with various lipid monolayers (b). The
histograms indicate the cumulative value of the surface pressure decrease (Δπ=Δπ1+Δπ2) expressed as the mean±SD (n=3). c. Kinetics studies of recombinant α-synuclein
(100 nM) interaction with GM3 (□) or cholesterol:GM3 (1:1, mol:mol) monolayers (■) prepared at an initial surface pressure of 17 mN.m−1. Each curve is representative of three
separate experiments (SDb10%). d. Interaction of recombinant α-synuclein (100 nM) with mixed cholesterol:GM3 (1:1, mol:mol) monolayers prepared at various values of the
initial surface pressure.
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reported to form functional ion channels through a colicin-like
mechanism [16,34]. In this case, a part of α-synuclein should cross the
plasmamembrane, and one can reasonably assume that themost apolar
part of the protein, which includes the tilted peptide, plays a key role in
this process [8]. Thehigh toxicity of the tilted peptide for both astrocytes
(Fig. 6) and neuroblastoma cells [24] and the ﬁnding that the
hydrophobic NAC fragment of α-synuclein, which contains the tilted
peptide, is toxic and forms ion channels [35,36], support this notion.
A possible topology of α-synuclein inserted in a lipid raft domain,
with its tilted peptide forming a stable complex with cholesterol, is
shown in Fig. 7b.Fig. 6. Effect of synthetic peptides 34–45 (■) and 67–78 (□) on the viability of rat
astrocytes (MTS assay). Results are expressed as the mean±SD (n=3).4.2. α-Synuclein association with lipid rafts involves both GSLs and
cholesterol
Do GSLs play a role in the cholesterol-dependent association of
α-synuclein with lipid rafts? Previous data have shown that the
internalization of α-synuclein is a lipid raft-dependent process that
involved GM1 [6], a ganglioside known to bind to α-synuclein [14].
Moreover, Ahn et al. have shown that both the NAC fragment (61–95)
and the N-terminal domain (1–60) are responsible for the membrane
translocation of α-synuclein [8]. This is consistent with our ﬁnding that
both the NAC fragment and the 1–60 region contain speciﬁc binding
sites for raft lipids, i.e. cholesterol for NAC and gangliosides for the 1–60
domain.
An important outcome of the present study is that the initial
interaction of α-synuclein with lipid rafts cannot be mediated by
cholesterol because this lipid ismasked by the large head groups of GSLs
which limit its accessibility to external ligands. This has been
demonstrated by using βMCD as a probe for the functional detection
of cholesterol in lipidmonolayers (Fig. 5b). Therefore,whenα-synuclein
lands on the exofacial leaﬂet of a lipid raft, the protein recognizes
ﬁrst the GSL head groups. Yet cholesterol is not totally passive during
this process. Our data showed that the sterol accelerated the inter-
action between α-synuclein and glycosphingolipids (Fig. 5c), most
likely by optimizing the conformation of the GSL that is required
for binding [28,37]. This is a kinetic effect, so that the afﬁnity of
α-synuclein for GSLs is not modiﬁed by cholesterol (Fig. 5d). By
modulating the conformation of GSLs, cholesterol favors the binding of
α-synuclein to lipid rafts and prevents the dilution of the protein in the
phosphatidylcholine-enriched liquid disordered phase of the mem-
brane [22].
Fig. 7. Potential topology of α-synuclein associated with a lipid raft. The raft contains
GM3, cholesterol (Chol), phosphatidylcholine (PC) and phosphatidylserine (PS). The
apolar domain containing the tilted peptide is in yellow. The α-helix facing the tilted
peptide is in green. The side chains of K-34, Y-39, and K-45 are indicated. a. The GBM of
α-synuclein (fragment 34–45) interacts with the sugar head groups of GM3, allowing
the CRAC domain (37–43) to reach cholesterol. In this conﬁguration, the tilted peptide
(67–78) remains outside the membrane and does not interact with cholesterol. b. A
deeper association between α-synuclein and the raft involves the binding of the tilted
peptide (67–78) with cholesterol. This implies that the GBM has been translocated
through the membrane.
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α-synuclein penetrates deeply between the sugar head groups of
glycosphingolipids and reaches the sugar-ceramide junction [14].
From all GBM residues, Tyr-39 is the one that is the most embedded in
themembrane. Since Tyr-39belongs to theCRACdomain ofα-synuclein,
this means that this residue is ideally located to form a hydrogen bond
with the OH group of cholesterol (Fig. 7a), a hallmark of CRAC-
cholesterol interactions [38]. This secondary interaction of α-synuclein
with cholesterol stabilizes the GBM at the polar–apolar interface of
the membrane. In this respect, the presence of a CRAC domain inside
the GBM is particularly advantageous because it allows the sequen-
tial interaction of α-synuclein with GSL and cholesterol during theFig. 8. Simultaneous presence of a GBM and a tilted peptide in amyloidogenic proteins. Th
Alzheimer's β peptide have been characterized in ref. [14]. The GBM of PrP has been characte
been characterized in refs. [24,45,46], respectively. SWISS-PROT accession numbers are indearly steps of membrane penetration. However, the lack of toxicity
of the GBM peptide for primary astrocytes indicates that the GBM
is not able, by itself, to cross the membrane. This implies that the
GBM needs the help of an auxilliary domain to ﬁnalize the insertion
of α-synuclein. The data reported by Ahn et al. [8] with recombinant
α-synuclein fragments suggested that this auxiliary domain is in-
cluded in the NAC region (61–95) of α-synuclein. The study of
Crowet et al. [24] demonstrated that the region of NAC encompassing
amino acid residues 67–78 has tilted, fusogenic and membrane-
disturbing properties. Our data showed that the tilted peptide of
α-synuclein binds cholesterol with high afﬁnity.
Tilted peptides are short helical protein fragments that are able to
disturb the organization of the molecular system into which they
insert. They are characterized by an asymmetric distribution of their
hydrophobic residues, which induces a tilted orientation (around 45°)
towards the membrane plane [39]. Because they induce an important
distortion of the membrane structure, tilted peptides are involved in
the fusion process triggered by viral glycoproteins [40]. Since viral
fusion is generally dependent upon the presence of cholesterol in the
target membrane [41], our ﬁnding that a tilted peptide can bind
cholesterol with high afﬁnity is particularly signiﬁcant and provides
new molecular insights in the function of cholesterol as a fusion
cofactor. As a matter of fact, although both cholesterol and GSLs have
been involved in virus fusion [19,41–43], we are still lacking a
universal model accounting for the fusion-promoting activity of lipid
rafts at the molecular level [43].
4.3. Hypothesis: a virus-like mechanism for amyloidogenic proteins?
We noticed that in addition to α-synuclein, other cholesterol-
binding amyloidogenic proteins such as Alzheimer's Aβ peptide and
PrP contain both a GBM [44] and a tilted peptide [45,46] (Fig. 8). The
GBM of these amyloidogenic proteins has been deﬁned on the basis of
a structural homology with the GBM of the HIV-1 surface envelope
glycoprotein gp120 [15]. Moreover, tilted peptides are also present in
the fusion glycoproteins of a wide range of viruses including HIV-1,
HTLV-I, Ebola, Marburg and Semliki forest virus [40]. Most of these
viruses interact with lipid rafts and require either cholesterol,
sphingolipids, or both to gain entry into host cells [43,47–50]. Indeed,
a common feature of virus fusion and amyloidogenesis mechanisms
is the involvement of lipid rafts [22,42]. Thus it is tempting to spec-
ulate that the interaction of both virus and amyloidogenic proteins
with lipid rafts is mediated by two distinct binding sites, one for
sphingolipids and the other for cholesterol. We have shown that
sphingolipid recognition involves a common sphingolipid-binding
motif (referred to as the SBD, which can be either a sphingomyelin-
binding domain or a GBM) in proteins that associate with lipid raftse GBM is colored in blue and the tilted peptide in red. The GBMs of α-synuclein and
rized in ref. [44]. The tilted peptides of α-synuclein, Alzheimer's β peptide, and Prp have
icated in parentheses.
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various cholesterol-binding proteins [25,38,51]. Our data showed
that in addition to CRAC domains, tilted peptides (at least the one of
α-synuclein) can also interact with cholesterol. The tilted peptide of
α-synuclein contains several amino acid residues (Ala, Thr and Val)
that can efﬁciently accommodate the protruding methyl groups of the
rough β-face of cholesterol [52] through van der Waals interactions
(Fig. 3). Moreover, our modeling studies suggested that the side chain
of Asn-79 could form a hydrogen bond with the OH group of
cholesterol. This unique combination of hydrogen bond and van der
Waals forces explains why the tilted peptide ofα-synuclein has such a
high afﬁnity for cholesterol. Further computational studies coupled
with physicochemical approaches may clarify whether binding to
cholesterol is a general property of tilted peptides or, conversely, why
only certain tilted peptides behave in this way to bind cholesterol and
to promote fusion.
5. Conclusions
In summary, we propose that the role of the GBM is to target the
amyloidogenic protein or the virus to cholesterol-enriched domains,
through GSL recognition. This ensures that cholesterol, although
masked at this early stage by the large head groups of GSLs [28,37], is
indeed present at the site of interaction, underneath the GSLs. In our
model, membrane penetration occurs through a cholesterol-depen-
dent mechanism involving a cholesterol-binding domain such as the
tilted peptide in the case of α-synuclein. The topology of the
cholesterol-tilted peptide complex (Fig. 3) indicates that when
cholesterol is perpendicular to the membrane bilayer, it stabilizes
the tilted orientation of the peptide, thus favoring its insertion.
According to our model, sphingolipids and cholesterol have two
distinct functions: trapping in lipid rafts for the sphingolipid, driving
force of the insertion/fusion process for cholesterol. This is supported
by the ﬁnding that cholesterol depletion of host cells did not reduce
alphaherpesvirus attachment but prevented subsequent virus entry
[53]. Overall, our data provide new insights into the molecular
mechanisms controling the association of proteins with lipid rafts,
underscoring the functional cooperation between GSLs and choles-
terol and explaining how cryptic cholesterol is detected by these
proteins. In this respect, there is a striking analogy between virus
fusion mechanisms and membrane insertion capability of amyloido-
genic proteins.
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